Stockreport

ImmunityBio (IBRX) Resubmits sBLA to FDA for ANKTIVA in Papillary Bladder Cancer [Yahoo! Finance]

ImmunityBio, Inc.  (IBRX) 
PDF highest upside potential . On March 9, ImmunityBio announced the resubmission of its sBLA to the FDA for ANKTIVA in combination with Bacillus Calmette-Guérin/BCG. This f [Read more]